Prevision Policy Clips | House E&C Drug Pricing/HR3 Hearing Will Hear Caution On Medicare Inflation Rebates

Advisory Committee Tracker: Another Landmark Diabetes Review In May; Provention May Get Positive Vote, But Approval Very Much In Doubt

Prevision Policy Clips | The Eagle Has Landed Former FDA Chief Scientist Luciana Borio As Board Member

FDA’s Pazdur Reasserts Influence Over ODAC With Split Vote On Opdivo In Second-Line Liver Cancer While Keytruda AA Unanimously Endorsed

Prevision Policy Clips | ODAC Accelerated Approval Review Is 4-2 In Favor Of Maintaining Indications

Merck Keytruda Third-Line Gastric Cancer Approval Likely To Be Pulled; Checkpoint Inhibitors Have Role, FDA Stresses – But Should Be At Earlier Stage

FDA Developing “N of 1” Therapy Requirements With Eye To Building Sustainable Business Models; CBER Needs 100 More Staffers To Meet Need, Marks Says

NTAP Extensions Proposed By CMS: Andexxa, Spravato Among Drugs In Line For Extra Year Of Enhanced Inpatient Payment By Medicare

Genentech’s Tecentriq, Merck’s Keytruda Take Different Routes To Protect Urothelial Indications: Coming-Soon Final Data; Continuing Unmet Need

Prevision Policy Clips | FDA Sends Shot Across The Bow For Industry On ClinicalTrials.Gov Noncompliance With Notice To Acceleron Pharma

Keytruda, Opdivo Accelerated Approval Reviews May Hinge On “Changing Landscape” In Liver Cancer; Do New Treatments Make Them Obsolete?

Genentech Tecentriq Accelerated Approval Should Be Maintained For Triple Negative Breast Cancer, FDA Committee Says, After Glitch-Filled Meeting

Prevision Policy Clips | Biden Will Reiterate Support For Rx Price Negotiation, But Not In His Infrastructure Bill

Antisense Oligonucleotide Nonclinical Testing Guidance Outlines Abbreviated Safety Package, Dose Selection

ICER Has Advice For FDA On Accelerated Approval Pathway; Value Assessment Group Also Offers More Dramatic Overhaul Ideas

Prevision Policy Clips | TIRF REMS Update Causing Issues For Patients, FDA Acknowledges

Merck Keytruda 1st Line Urothelial Cancer Indication May Be In Stronger Position Than Genentech’s Tecentriq Heading Into ODAC Meeting

Keytruda Gastric Cancer Indication Faces Tough Challenge During ODAC Accelerated Approval Review; Low Use May Make For Easier Withdrawal

Genentech’s Tecentriq For Triple Negative Breast Cancer: FDA Seems Open For Different Confirmatory Study; Will Advisory Committee Agree?

Prevision Policy Clips | FDA Publishes Antisense Oligonucleuotide Nonclinical Testing Guidance

“FDA-Agreed” Warning Ready For J&J COVID-19 Vaccine Restart; ACIP Is Satisfied With Enhanced Surveillance, Rarity Of TTS Events

ODAC Will Deliver Straight Yes/No Vote On Whether Six Accelerated Approvals Can Be Preserved; FDA Also Requesting Advice On Additional Studies

Prevision Policy Clips | CMS Nominee Brooks-LaSure, HHS Deputy Palm Clear Finance Committee, But Tie Vote On CMS

CAR-Ts For Multiple Myeloma Show Net Health Benefit, ICER Panel Says, But Dubious Value For The Price; GSK’s Blenrep Is Priced In Line With QALY Benefit, But Panel Still Doubts Value

FDA Takes Firm Stance On “Dangling” Accelerated Approvals Ahead Of ODAC But Offers Opening For Alternatives To Withdrawal